Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/39470
Title: miR-378 reduces mesangial hypertrophy and kidney tubular fibrosis via MAPK signalling.
Authors: Ricardo S.D.;Wang B.;Yao K.;Wise A.F.;Lau R.;Shen H.-H.;Tesch G.H.
Monash Health Department(s): Nephrology
Institution: (Wang, Yao, Wise, Lau, Ricardo) Department of Anatomy and Developmental Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia (Shen) Department of Materials Engineering, Monash University, Clayton, Australia (Tesch) Department of Nephrology, Monash University Department of Medicine, Monash Medical Centre, Clayton, VIC, Australia
Issue Date: 23-Mar-2017
Copyright year: 2017
Publisher: Portland Press Ltd
Place of publication: United Kingdom
Publication information: Clinical Science. 131 (5) (pp 411-423), 2017. Date of Publication: 2017.
Journal: Clinical Science
Abstract: The regulatory role of a novel miRNA, miR-378, was determined in the development of fibrosis through repression of the MAPK1 pathway, miR-378 and fibrotic gene expression was examined in streptozotocin (STZ)-induced diabetic mice at 18 weeks or in unilateral ureteral obstruction (UUO) mice at 7 days. miR-378 transfection of proximal tubular epithelial cells, NRK52E and mesangial cells was assessed with/without endogenous miR-378 knockdown using the locked nucleic acid (LNA) inhibitor. NRK52E cells were co-transfected with the mothers against decapentaplegic homolog 3 (SMAD3) CAGA reporter and miR-378 in the presence of transforming growth factor-beta (TGF-beta1) was assessed. Quantitative polymerase chain reaction (qPCR) showed a significant reduction in miR-378 (P < 0.05) corresponding with up-regulated type I collagen, type IV collagen and a-smooth muscle actin (SMA) in kidneys of STZ or UUO mice, compared with controls. TGF-beta1 significantly increased mRNA expression of type I collagen (P < 0.05), type IV collagen (P < 0.05) and alpha-SMA (P < 0.05) in NRK52E cells, which was significantly reduced (P < 0.05) following miR-378 transfection and reversed following addition of the LNA inhibitor of endogenous miR-378. Overexpression of miR-378 inhibited mesangial cell expansion and proliferation in response to TGF-beta1, with LNA-miR-378 transfection reversing this protective effect, associated with cell morphological alterations. The protective function of MAPK1 on miR-378 was shown in kidney cells treated with the MAPK1 inhibitor, selumetinib, which inhibited mesangial cell hypertrophy in response to TGF-beta1. Taken together, these results suggest that miR-378 acts via regulation of the MAPK1 pathway. These studies demonstrate the protective function of MAPK1, regulated by miR-378, in the induction of kidney cell fibrosis and mesangial hypertrophy.Copyright © 2017 The Author(s).
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1042/CS20160571
Link to associated publication: Click here for full text options
PubMed URL: 28053239 [http://www.ncbi.nlm.nih.gov/pubmed/?term=28053239]
ISSN: 0143-5221
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/39470
Type: Article
Subjects: article
cell expansion
cell proliferation
cell protection
cell structure
controlled study
drug efficacy
drug mechanism
gene expression regulation
gene repression
gene silencing
genetic transfection
human
human cell
*kidney hypertrophy/pc [Prevention]
kidney proximal tubule
kidney tubule cell
*kidney tubule damage/pc [Prevention]
luciferase assay
male
mesangium cell
mouse
nonhuman
*obstruction-induced renal fibrosis/pc [Prevention]
polymerase chain reaction
priority journal
quantitative analysis
animal tissue
renal protection
reporter gene
signal transduction
streptozotocin-induced diabetes mellitus
upregulation
alpha smooth muscle actin/ec [Endogenous Compound]
*antifibrotic agent/dv [Drug Development]
*antifibrotic agent/pd [Pharmacology]
beta actin/ec [Endogenous Compound]
collagen type 1/ec [Endogenous Compound]
collagen type 4/ec [Endogenous Compound]
fibronectin/ec [Endogenous Compound]
locked nucleic acid
messenger RNA/ec [Endogenous Compound]
*microRNA/dv [Drug Development]
*microRNA/ec [Endogenous Compound]
*microRNA/pd [Pharmacology]
*mitogen activated protein kinase 1/ec [Endogenous Compound]
recombinant transforming growth factor beta1
selumetinib/dv [Drug Development]
selumetinib/pd [Pharmacology]
Smad3 protein/ec [Endogenous Compound]
streptozocin
transforming growth factor beta1/ec [Endogenous Compound]
unclassified drug
*urinary tract agent/dv [Drug Development]
*urinary tract agent/pd [Pharmacology]
*microRNA 378/dv [Drug Development]
*microRNA 378/ec [Endogenous Compound]
*microRNA 378/pd [Pharmacology]
rat
animal model
animal experiment
animal cell
gene repression
gene silencing
genetic transfection
human
human cell
*kidney hypertrophy / *prevention
kidney proximal tubule
kidney tubule cell
*kidney tubule damage / *prevention
luciferase assay
male
mesangium cell
mouse
nonhuman
*obstruction-induced renal fibrosis / *prevention
polymerase chain reaction
priority journal
quantitative analysis
rat
renal protection
reporter gene
signal transduction
Article
upregulation
streptozotocin-induced diabetes mellitus
cell expansion
cell proliferation
cell protection
cell structure
controlled study
drug efficacy
drug mechanism
gene expression regulation
animal cell
animal experiment
animal model
animal tissue
Appears in Collections:Articles

Show full item record

Page view(s)

6
checked on Aug 17, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.